Fierce Pharma

OCTOBER 30, 2024

Biopharma production efforts are set to receive a big boost in the U.K. thanks to a new budget rolled out by the Labour Party following this summer’s general election. | As part of the new budget presented Wednesday by the U.K.’s

Manufacturing 209

Manufacturing Biopharma Medical 209

Fierce Pharma

DECEMBER 19, 2024

In a move that follows an increasingly common trend in biopharma M&A, Novartis is shedding sites and staffers from the German cancer biotech it acquired earlier this year. Novartis confirmed Thursday that its closing down MorphoSys sites in Munich and Boston in a move thats expected to result in around 330 layoffs.

Biopharma 201

Biopharma 201

Fierce Pharma

NOVEMBER 5, 2024

works to pump fresh cash into the local biopharma scene, London’s Accord Healthcare is capitalizing on the government’s renewed willingness to chip in. As the U.K. Flush with a 50 million pound sterling ($65 million) joint investment deal from the U.K.,

Biopharma 170

Biopharma Manufacturing Healthcare Healthcare 170

Fierce Pharma

MARCH 11, 2024

The decades-long wait for an effective treatment for metabolic dysfunction-associated steatohepatitis (MASH) has ended, as the FDA has approved the first drug for the fatty liver disease. | The decades-long wait for an effective treatment for metabolic dysfunction-associated steatohepatitis (MASH) has ended.

FDA 349

FDA Biopharma 349

Fierce Pharma

DECEMBER 2, 2024

Department of Health and Human Services immediately sent waves of speculation swirling throughout the biopharma industry. | Kennedy Jr.’s s appointment last month to lead the U.S. The former FDA Commissioner pointed to the threat of measles if vaccination rates were to decline by 5%.

Biopharma 67

Biopharma FDA Leads 67

Fierce Pharma

AUGUST 20, 2024

As House lawmakers prepare for a September vote on the controversial BIOSECURE Act, the House Select Committee on the CCP is expanding the scope of its scrutiny on China's biopharma ecosystem. |

Biopharma 289

Biopharma FDA 289

MedCity News

JULY 19, 2024

A new eBook from MedCity News highlights the variety of technologies emerging from AI tech developers across the healthcare landscape from health tech startups to healthcare organizations, biopharma companies, and a medtech giant. It also explores the ethical issues AI in healthcare presents.

Ethics 299

Ethics Biopharma Healthcare Healthcare 299

MedCity News

AUGUST 13, 2024

Baxter International is selling its kidney care business for less than it was able to fetch for its much smaller biopharma solutions segment last year. A unit within kidney care took a goodwill impairment charge, Baxter’s financial reports show. The post Private Equity Buys Another Piece of Baxter as Carlyle Scoops Up Kidney Care Biz for $3.8B

Biopharma 299

Biopharma 299

MedCity News

FEBRUARY 19, 2025

We’re looking for biopharma startups focused on infectious diseases, medtech/diagnostics startups supporting chronic disease management, and health tech startups seeking to improve care navigation and coordination and developing AI tech.

Healthcare 147

Healthcare Healthcare Biopharma Management 147

Fierce Pharma

NOVEMBER 6, 2024

As other biopharma giants have divested their generics units to focus on the development and commercialization of innovative drugs, Teva has relied on its copycat business to help trigger its rebou | Teva revealed booming third-quarter sales for its generics and biosimilars. In the U.S., revenue from the knockoffs came in at $1.1

Biopharma 132

Biopharma Sales 132

PharmaVoice

MARCH 3, 2025

Consumers want more from biopharma. Next-generation direct-to-patient programs can deliver.

Patients 246

Patients Biopharma 246

MedCity News

SEPTEMBER 13, 2024

Zenas BioPharma and MBX Biosciences also went public; all three companies upsized their IPOs. Bicara Therapeutics’ IPO raised $315 million raised for Phase 3 testing of a bifunctional antibody drug with potential to become a first-line treatment for head and neck cancers.

Biopharma 287

Biopharma Pharma 287

Fierce Pharma

NOVEMBER 27, 2024

On a routine basis in recent years, headlines about layoffs in the biopharma industry have surfaced as companies large and small have been cutting costs and restructuring. |

Biopharma 167

Biopharma Prospecting 167

MedCity News

JANUARY 30, 2025

Infectious disease is the focus of the biopharma track at INVEST Pitch Perfect May 20-21 in Chicago. Register today! The post A Snapshot of Five Contenders to Combat Infectious Diseases in the Post-Pandemic Landscape appeared first on MedCity News.

Biopharma 264

Biopharma 264

Fierce Pharma

NOVEMBER 18, 2024

may not rock the boat as much as feared for the biopharma industry. Robert F. | In a contrarian take offered by BMO Capital Markets' Evan Seigerman, the analyst said Robert F. Kennedy Jr.

Biopharma 274

Biopharma FDA Marketing 274

MedCity News

MARCH 9, 2025

Neurotech Pharmaceuticals surgically implanted cell and gene therapy, Encelto, is now FDA approved to treat macular telangectasia type 2 (MacTel). Its the first therapy for this rare retinal degeneration disorder. The post Gene Therapy in an Implant: Neurotech Lands First FDA Approval in Rare Vision Disorder appeared first on MedCity News.

FDA 298

FDA Pharmaceutical Biopharma 298

MedCity News

DECEMBER 5, 2024

The startup’s first disease target is chronic inflammatory demyelinating polyneuropathy (CIDP), which can be treated with a blockbuster Argenx drug. Nuvig aims to show its drug can offer a better way to treat this disease and other autoimmune conditions.

Biopharma 302

Biopharma Pharma 302

MedCity News

DECEMBER 10, 2024

Arcellxs cell therapy for multiple myeloma has shown no signs of the parkinsonism complication observed in clinical testing of Carvykti, a rival product from partners Johnson & Johnon and Legend Biotech. Arcellx is developing its CAR T-treatment under a partnership with Gilead Sciences.

Safety 296

Safety Manufacturing Biopharma Pharma 296

MedCity News

NOVEMBER 14, 2024

The PTC Therapeutics gene therapy, Kebilidi, treats an enzyme deficiency that affects the body’s ability to produce dopamine, a neurotransmitter important for motor control. FDA approval for the product comes two years after it won its first regulatory approvals in Europe.

FDA 315

FDA Biopharma Pharma 315

MedCity News

NOVEMBER 26, 2024

Roche is acquiring Poseida Therapeutics, a biotech developing allogeneic cell therapies for cancers and immunological indications. The two companies have been partners in hematological malignancies since 2022. The post Roche Expands Its Scope in Allogeneic Cell Therapy With $1B Poseida Therapeutics Acquisition appeared first on MedCity News.

Biopharma 311

Biopharma Pharma 311

MedCity News

MARCH 7, 2025

J&J said aticaprant showed insufficient efficacy in a Phase 3 test in major depressive disorder. The disappointing result follows the Phase 3 failure of a Neumora Therapeutics drug that addresses the same central nervous system target.

Biopharma 280

Biopharma Pharma 280

MedCity News

NOVEMBER 10, 2024

Autolus Therapeutics’ Aucatzyl is now FDA approved for treating advanced cases of B-cell precursor acute lymphoblastic leukemia. While it goes after the same target as Gilead Sciences’ Tecartus, Autolus engineered its CAR T-therapy with properties that could improve safety, efficacy, and durability.

FDA 315

FDA Engineering Safety Biopharma 315

MedCity News

NOVEMBER 8, 2024

The FDA has proposed removing oral phenylephrine from its guidelines for over-the-counter drugs due to inefficacy as a decongestant. Use of this ingredient in cold and allergy medicines grew after a federal law required that pseudoephedrine-containing products be kept behind pharmacy counters.

FDA 306

FDA Marketing Medicine Biopharma 306

MedCity News

NOVEMBER 22, 2024

A patient death in a clinical trial usually prompts the FDA to impose a clinical hold. But Neurogene is able to avoid a lengthy clinical trial pause largely because of its participation in an FDA pilot program intended to speed up the development of therapies for rare diseases.

FDA 297

FDA Patients Biopharma Pharma 297

MedCity News

DECEMBER 4, 2024

The Glp-1 battle heats with new preliminary data from Eli Lilly showing that patients using its weight loss drug Zepbound lost more weight on average in 72 weeks than those on Novo Nordisk’s Wegovy. The post Video: Battle of the Bulge – Wegovy vs. Zepbound appeared first on MedCity News.

Patients 288

Patients Biopharma 288

MedCity News

NOVEMBER 1, 2024

Novo Nordisk’s Wegovy achieved statistically significant improvement in a Phase 3 study in the fatty liver disease MASH. Based on these preliminary results, the company plans to seek U.S. and European Union approvals in this indication in 2025.

FDA 286

FDA Biopharma Pharma 286

MedCity News

NOVEMBER 6, 2024

Acadia Pharmaceuticals did not disclose the buyer of the priority review voucher. The biotech received the voucher last year alongside the regulatory decision that made its drug Daybue the first FDA-approved treatment for the rare disease Rett syndrome.

FDA 298

FDA Pharma Pharmaceutical Biopharma 298

MedCity News

FEBRUARY 17, 2025

Mercks implementation of artificial intelligence in drug research includes analyzing years of existing Merck clinical data to help identify which drugs and drug combinations to pursue. But Merck executive Matt Studney said AI is tool to help, not replace humans.

Biopharma 273

Biopharma Pharma 273

MedCity News

NOVEMBER 14, 2024

In an interview, Rabah talked about the promise of AI, where it can have the most impact, while also responding to the IRA and high drug prices in the United States. The post CEO of Otsuka North America: Are We Getting better access with AI? appeared first on MedCity News.

Pharmaceutical 304

Pharmaceutical Biopharma Healthcare Healthcare 304

MedCity News

NOVEMBER 14, 2024

Merck is acquiring global rights to a bispecific antibody from LaNova Medicines that blocks two cancer targets, PD-1 and VEGF. The deal comes one day after BioNTech announced an $800 million acquisition that gives it full rights to a molecule in this hot class of cancer drug candidates.

Medicine 306

Medicine Biopharma Pharma 306

MedCity News

NOVEMBER 17, 2024

Vesalius Therapeutics’ AI-based technology finds novel targets and intervention points for subgroups of patients within a common disease. A small molecule that Vesalius has been developing for a novel Parkinson’s disease target is now headed to GSK, which has licensed global rights.

Patients 306

Patients Biopharma Pharma 306

MedCity News

JANUARY 9, 2025

Verdiva Bios once-a-week oral GLP-1 drug is ready for Phase 2 testing. The drug, made with a proprietary technology that enables oral dosing, was licensed from Sciwind Biosciences. The post Metabolic Meds Startup Verdiva Launches With $411M and a Weekly Oral GLP-1 Drug appeared first on MedCity News.

Biopharma 278

Biopharma Pharma 278

MedCity News

FEBRUARY 2, 2025

Investors showed appetite for Metseras IPO, as shares of the clinical-stage metabolic medicines biotech popped 47% in their Nasdaq debut. Maze Therapeutics and Beta Bionics also priced IPOs; the three companies raised $636 million combined.

Medicine 297

Medicine Biopharma Pharma 297

MedCity News

JANUARY 17, 2025

With technology advancements specifically in the field of AI, there is a clear line of sight in making it mainstream. Here are some of the ways AI is helping to accelerate the adoption of PM. The post Precision Medicine: Becoming More Real With AI? appeared first on MedCity News.

Medicine 345

Medicine Pharmaceutical Biopharma Pharma 345

MedCity News

NOVEMBER 12, 2024

Neurogene’s Rett syndrome gene therapy has preliminary data supporting safety and efficacy of the one-time treatment. But a late-breaking report of a serious complication in a patient who received the high dose sent shares of the biotech downward.

Safety 277

Safety Patients Biopharma 277

MedCity News

NOVEMBER 20, 2024

Valora Therapeutics’ antibody lectin chimeras, or AbLecs, target glyco-immune checkpoints, pathways that modulate cellular communication with the immune system. The startup’s science is based on research from Carolyn Bertozzi, a Stanford professor who was awarded the 2022 Nobel Prize in Chemistry.

Biopharma 298

Biopharma 298

MedCity News

JANUARY 23, 2025

Astellas Pharma still looks to grow in cancer with a pipeline that includes internally developed programs that could stand out in oncology. But the drugmaker sees additional growth opportunities in ophthalmology and neuromuscular disorders, Chief Medical Officer Tadaaki Taniguci said.

Pharma 278

Pharma Medical Biopharma 278